S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:DICE

DICE Therapeutics Stock Forecast, Price & News

$16.86
-0.50 (-2.88%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.06
$18.23
50-Day Range
$16.86
$37.54
52-Week Range
$16.06
$40.50
Volume
204,206 shs
Average Volume
362,814 shs
Market Capitalization
$644.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive DICE News and Ratings via Email

Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


DICE Therapeutics logo

About DICE Therapeutics

DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DICE
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$644.56 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/16/2022
Next Earnings (Estimated)
2/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

816th out of 1,405 stocks

Pharmaceutical Preparations Industry

391st out of 678 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












DICE Therapeutics (NASDAQ:DICE) Frequently Asked Questions

Is DICE Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DICE Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DICE Therapeutics stock.
View analyst ratings for DICE Therapeutics
or view top-rated stocks.

When is DICE Therapeutics' next earnings date?

DICE Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for DICE Therapeutics
.

How were DICE Therapeutics' earnings last quarter?

DICE Therapeutics Inc (NASDAQ:DICE) released its earnings results on Friday, November, 12th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $1.77.
View DICE Therapeutics' earnings history
.

What price target have analysts set for DICE?

3 Wall Street analysts have issued 1 year price targets for DICE Therapeutics' shares. Their forecasts range from $41.00 to $60.00. On average, they expect DICE Therapeutics' share price to reach $49.00 in the next year. This suggests a possible upside of 190.6% from the stock's current price.
View analysts' price targets for DICE Therapeutics
or view top-rated stocks among Wall Street analysts.

When did DICE Therapeutics IPO?

(DICE) raised $160 million in an IPO on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share.

What is DICE Therapeutics' stock symbol?

DICE Therapeutics trades on the NASDAQ under the ticker symbol "DICE."

When does DICE Therapeutics' lock-up period expire?

DICE Therapeutics' lock-up period expires on Monday, March 14th. DICE Therapeutics had issued 12,000,000 shares in its IPO on September 15th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of DICE Therapeutics?

Shares of DICE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DICE Therapeutics' stock price today?

One share of DICE stock can currently be purchased for approximately $16.86.

How much money does DICE Therapeutics make?

DICE Therapeutics has a market capitalization of $644.56 million.

How many employees does DICE Therapeutics have?

DICE Therapeutics employs 2,021 workers across the globe.

What is DICE Therapeutics' official website?

The official website for DICE Therapeutics is www.dicemolecules.com.

Where are DICE Therapeutics' headquarters?

How can I contact DICE Therapeutics?

DICE Therapeutics' mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-566-1420 or via email at [email protected].


This page was last updated on 1/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.